Skip to content
    MPM Capital logo

    MPM Capital

    Boston, Massachusetts, United StatesFounded 1996
    mpmbioimpact.comLinkedIn
    Biotech & Life SciencesHealthcare

    MPM Capital is a world-leading biotechnology investment firm with nearly three decades of experience creating and investing in companies that seek to translate scientific innovations into cures for major diseases. The firm invests across the biotech landscape through early-stage venture capital funds and impact/public equities products via its affiliate BioImpact Capital, managing over $3 billion in AUM.

    31% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $73.3M (across 105 rounds with reported amounts).

    Find people at MPM Capital on Goldilocks AI

    Portfolio

    80

    Fund Size

    $850M

    Top Stage

    Series A

    Last 12 Mo

    2

    Team

    AG

    Ansbert Gadicke

    Managing Partner

    CB

    Christiana Bardon

    Managing Partner

    GS

    Greg Sieczkiewicz

    Managing Partner

    JP

    John Peng

    Managing Partner

    AG

    Ansbert Gadicke

    Managing Director

    EH

    Ed Hurwitz

    Managing Director

    TF

    Todd Foley

    Managing Director

    DB

    Diana Brainard

    Executive Partner

    ES

    Elizabeth Stoner

    Entrepreneur Partner

    KL

    Kristen Laguerre

    Executive Partner

    RR

    Rami Rahal

    Partner

    PW

    Philip Wen

    Investment Professional

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    113 investments
    CompanyRoundAmountDate
    CCrossbowSeries B$77MJan 2026
    Protego Bio logoProtego BioSeries B$130MDec 2025
    PProtego BiopharmaSeries B$130MDec 2025
    DDBV Technologies S.A.Unknown$306.9MMar 2025
    Umoja logoUmojaSeries C$100MJan 2025
    Umoja Biopharma logoUmoja BiopharmaSeries C$100MJan 2025
    PProtego BiopharmaSeries B$130MJan 2025
    Reunion Neuroscience logoReunion NeuroscienceSeries A$103MMay 2024
    Firefly Bio logoFirefly BioSeries A$94MJan 2024
    AstronauTx logoAstronauTxSeries A$61MOct 2023
    Deka Biosciences logoDeka BiosciencesSeed$20MJan 2023
    Photys logoPhotysSeries A$75MSep 2022
    Aktis Oncology logoAktis OncologySeries A$84MAug 2022
    Photys Therapeutics logoPhotys TherapeuticsSeries A$75MJan 2022
    Protego Bio logoProtego BioSeries A$51MNov 2021
    PProtego BiopharmaSeries A$51MNov 2021
    Umoja logoUmojaSeries B$210MJun 2021
    WWerewolf TherapeuticsSeries A$120MApr 2021
    Orna Therapeutics logoOrna TherapeuticsSeries A$80MFeb 2021
    WWerewolf TherapeuticsSeries B$72MJan 2021
    ReCode Therapeutics logoReCode TherapeuticsSeries B$50MJan 2021
    Entrada logoEntradaSeries B$116MJan 2021
    RReCodeSeries B$50MJan 2021
    Cullinan Oncology logoCullinan OncologyIpo$287.4MJan 2021
    Orna Therapeutics logoOrna TherapeuticsSeries A$80MJan 2021
    Page 1 of 5

    Top Co-Investors

    OrbiMed13 shared
    Arkin Bio Ventures9 shared
    New Enterprise Associates9 shared
    Astellas Venture Management9 shared
    Pfizer Ventures8 shared
    Omega Funds7 shared
    Lightspeed Venture Partners7 shared
    MRL Ventures Fund7 shared
    Longwood Fund7 shared
    Alexandria Venture Investments7 shared
    Redmile Group7 shared
    The Invus Group, LLC7 shared
    Amgen Ventures7 shared
    InterWest Partners7 shared
    Abingworth LLP7 shared
    Qiming Venture Partners USA6 shared
    Deerfield6 shared
    RA Capital Management6 shared
    Cormorant Asset Management6 shared
    Domain Associates6 shared

    Last updated: 7 October 2026